Molnupiravir, an oral antiviral treatment for COVID-19
Background Easily distributed oral antivirals are urgently needed to treat coronavirus
disease-2019 (COVID-19), prevent progression to severe illness, and block transmission of …
disease-2019 (COVID-19), prevent progression to severe illness, and block transmission of …
Molnupiravir and risk of post-acute sequelae of covid-19: cohort study
Objective To examine whether treatment with the antiviral agent molnupiravir during the first
five days of SARS-CoV-2 infection is associated with reduced risk of post-acute adverse …
five days of SARS-CoV-2 infection is associated with reduced risk of post-acute adverse …
[HTML][HTML] Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials
TK Patel, PB Patel, M Barvaliya, MK Saurabh… - Journal of Infection and …, 2021 - Elsevier
Background Lopinavir-ritonavir is a repurposed drug for coronavirus disease-2019 (COVID-
19). In this study, a pooled effect of lopinavir-ritonavir on mortality, virological cure …
19). In this study, a pooled effect of lopinavir-ritonavir on mortality, virological cure …
Favipiravir for treating patients with novel coronavirus (COVID-19): protocol for a systematic review and meta-analysis of randomised clinical trials
Introduction An outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
was reported in Wuhan, China, in mid-December 2019, and declared a pandemic by the …
was reported in Wuhan, China, in mid-December 2019, and declared a pandemic by the …
[HTML][HTML] First-generation oral antivirals against SARS-CoV-2
Background Oral drugs against severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) have received emergency use authorization for the treatment of mild-to-moderate …
CoV-2) have received emergency use authorization for the treatment of mild-to-moderate …
[HTML][HTML] Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study
HM Dabbous, S Abd-Elsalam, MH El-Sayed… - Archives of …, 2021 - Springer
No specific antiviral drugs have been approved for the treatment of COVID-19. This study
aimed to evaluate the efficacy of favipiravir in treatment of COVID-19. This was a multicenter …
aimed to evaluate the efficacy of favipiravir in treatment of COVID-19. This was a multicenter …
[HTML][HTML] Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2 …
WHK Schilling, P Jittamala, JA Watson… - The Lancet Infectious …, 2024 - thelancet.com
Background Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-
19 antiviral treatments, but their antiviral activities in patients have not been compared …
19 antiviral treatments, but their antiviral activities in patients have not been compared …
[HTML][HTML] Making statistical sense of the molnupiravir MOVe-OUT clinical trial
K Thorlund, K Sheldrick… - The American Journal …, 2022 - ncbi.nlm.nih.gov
Oral therapies for the early treatment of COVID-19 may prevent disease progression and
health system overcrowding. A new oral therapeutic named molnupiravir has been …
health system overcrowding. A new oral therapeutic named molnupiravir has been …
[HTML][HTML] Molnupiravir and its antiviral activity against COVID-19
L Tian, Z Pang, M Li, F Lou, X An, S Zhu… - Frontiers in …, 2022 - frontiersin.org
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) constitutes a major worldwide public health threat …
syndrome coronavirus 2 (SARS-CoV-2) constitutes a major worldwide public health threat …
[HTML][HTML] RdRp inhibitors and COVID-19: Is molnupiravir a good option?
SMR Hashemian, MH Pourhanifeh, MR Hamblin… - Biomedicine & …, 2022 - Elsevier
Rapid changes in the viral genome allow viruses to evade threats posed by the host immune
response or antiviral drugs, and can lead to viral persistence in the host cells. RNA …
response or antiviral drugs, and can lead to viral persistence in the host cells. RNA …